share_log

AbbVie | 8-K: Closure of Notes Sale Pursuant to Underwriting Agreement

艾伯维公司 | 8-K:根据承销协议完成票据发行

美股sec公告 ·  02/26 17:11
Moomoo AI 已提取核心信息
On February 22, 2024, AbbVie Inc. successfully entered into an underwriting agreement with major financial institutions including Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, BofA Securities, Inc., and Citigroup Global Markets Inc. The agreement facilitated a public offering where AbbVie issued $15.0 billion in senior notes with varying maturities ranging from 2027 to 2064. The notes were registered under the Securities Act of 1933, as amended, and are unsecured and unsubordinated, ranking equally with AbbVie's other similar obligations. AbbVie intends to use the net proceeds from the notes to prepay a term loan, fund acquisitions, repay borrowings under its commercial paper program, cover fees and expenses related to these activities, and for general corporate purposes. The offering was made pursuant to a prospectus supplement filed with the SEC on February 26, 2024.
On February 22, 2024, AbbVie Inc. successfully entered into an underwriting agreement with major financial institutions including Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, BofA Securities, Inc., and Citigroup Global Markets Inc. The agreement facilitated a public offering where AbbVie issued $15.0 billion in senior notes with varying maturities ranging from 2027 to 2064. The notes were registered under the Securities Act of 1933, as amended, and are unsecured and unsubordinated, ranking equally with AbbVie's other similar obligations. AbbVie intends to use the net proceeds from the notes to prepay a term loan, fund acquisitions, repay borrowings under its commercial paper program, cover fees and expenses related to these activities, and for general corporate purposes. The offering was made pursuant to a prospectus supplement filed with the SEC on February 26, 2024.
2024年2月22日,艾伯维公司成功与包括摩根士丹利公司在内的主要金融机构签订了承保协议。有限责任公司、摩根大通证券有限责任公司、美银证券公司和花旗集团环球市场公司该协议促进了公开募股,艾伯维发行了150亿美元的优先票据,期限从2027年到2064年不等。这些票据是根据经修订的1933年《证券法》注册的,是无抵押和无次级票据的,与艾伯维的其他类似债务持平。艾伯维打算将票据的净收益用于预付定期贷款、为收购提供资金、偿还其商业票据计划下的借款、支付与这些活动相关的费用和开支以及一般公司用途。此次发行是根据2024年2月26日向美国证券交易委员会提交的招股说明书补充文件进行的。
2024年2月22日,艾伯维公司成功与包括摩根士丹利公司在内的主要金融机构签订了承保协议。有限责任公司、摩根大通证券有限责任公司、美银证券公司和花旗集团环球市场公司该协议促进了公开募股,艾伯维发行了150亿美元的优先票据,期限从2027年到2064年不等。这些票据是根据经修订的1933年《证券法》注册的,是无抵押和无次级票据的,与艾伯维的其他类似债务持平。艾伯维打算将票据的净收益用于预付定期贷款、为收购提供资金、偿还其商业票据计划下的借款、支付与这些活动相关的费用和开支以及一般公司用途。此次发行是根据2024年2月26日向美国证券交易委员会提交的招股说明书补充文件进行的。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息